Twist Bioscience (TWST) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power of a changi ...

Twist Bioscience (NASDAQ: TWST ) report strong results in the first quarter of FY25, driven by its SynBio and NGS segments. While Twist's core businesses continue to thrive in a tough macro environment, there remain questions about the company's growth initiatives. Twist'sRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess risk adjusted returns can be a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38720 Twist Bioscience Corporation (Exact Name of Registrant as Specified in its Charter) Delaware 46-2058 ...

Twist Bioscience Corporation (NASDAQ:TWST) Q1 2025 Earnings Conference Call February 3, 2025 8:00 AM ET Company Participants Angela Bitting - Senior Vice President of Corporate Affairs Emily Leproust - Chief Executive Officer and Co-Founder Patrick Finn - President and Chief Operating Officer Adam Laponis - Chief Financial Officer Conference Call Participants Matthew Sykes - Goldman Sachs Luke Sergott - Barclays Subbu Nambi - Guggenheim Securities Catherine Schulte - Baird Brendan Smith - TD Cowen Vijay Kum ...

Twist Bioscience (TWST) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.52%. A quarter ago, it was expected that this maker of synthetic DNA for the biotechnology industry would post a loss of $0.73 per share when it actually produced a loss of $0.59, delivering a surprise of 19.18%.Over t ...

Fiscal 2025 1Q Financial Results F E B R U A R Y 2 0 2 5 Agenda Welcome 2 | TWIST BIOSCIENCE | PROPRIETARY Business Highlights Patrick Finn President and Chief Operating Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive Officer Q&A Session Angela Bitting SVP, Corporate Affairs; Chief Corporate Responsibility Officer Quarterly Highlights Emily Leproust Chief Executive Officer Legal Disclaimers This presentation contains forward-lookin ...

— Expect revenue in the range of $372 million to $379 million for full year fiscal 2025; expect gross margin over 50% for 4QFY25 — SOUTH SAN FRANCISCO, Calif. -- (February 3, 2025) — Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today reported financial results and business highlights for the first quarter of fiscal 2025 ended December 31, 2024. "We ended the first quarter of fiscal 2025 with our eighth con ...

Investors might want to bet on Twist Bioscience (TWST) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individ ...

Twist Bioscience (TWST) shares soared 9.9% in the last trading session to close at $47.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 4.7% gain over the past four weeks.Last month, the company announced robust financial results for the fiscal fourth quarter and full-year fiscal 2024. This might have driven the share price rally.This maker of synthetic DNA for the biotechnology industry is expected to post quarterly loss of $ ...

A downtrend has been apparent in Twist Bioscience (TWST) lately. While the stock has lost 9.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future ear ...